source
- BrainChild Bio secures $119M Series A to advance CAR-T therapy for deadly pediatric brain tumorBrainChild Bio announced a $119 million Series A financing round aimed at moving its CAR‑T programs for central nervous system cancers in children forward. The company’s lead candidate, BCB-276, w…
- BrainChild secures $116M to advance CAR-T therapies for rare pediatric brain tumorsBrainChild Bio, a Seattle‑based biotech spun out of Seattle Children’s Hospital, announced it has raised $116 million in venture financing. The capital will fund the development of its CAR‑T cell t…